Enanta Pharmaceuticals (ENTA) Amortizatization of Intangibles (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported Amortizatization of Intangibles of -$302000.0 for Q1 2026, up 62.99% on a YoY basis from -$185287.2 in Q1 2025, and down 1410.0% quarter-over-quarter from -$20000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported Amortizatization of Intangibles for 15 years, with the latest figure at -$302000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 62.99% year-over-year to -$302000.0; the trailing twelve-month figure through Mar 2026 stood at $623000.0 (up 5763.64% YoY), and the FY2025 full-year result was -$503000.0, down 144.2% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at -$302000.0, down from -$20000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $1.4 million in Q2 2023, with the low at -$816000.0 in Q1 2025.
- Historically, Amortizatization of Intangibles has averaged $149647.1 across 5 years, with a median of -$20000.0 in 2025.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles surged 1778.12% — and 2025, when it plunged 3164.0%.
- Enanta Pharmaceuticals' Amortizatization of Intangibles stood at $339000.0 in 2022, then sank by 180.83% to -$274000.0 in 2023, then sank by 130.66% to -$632000.0 in 2024, then surged by 96.84% to -$20000.0 in 2025, then slumped by 1410.0% to -$302000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$302000.0 (Q1 2026), -$20000.0 (Q4 2025), and $958000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | -302,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -302,000.00 |
| Mar 31, 2026 | -302,000.00 |
| Dec 31, 2025 | -20,000.00 |
| Dec 31, 2025 | -20,000.00 |
| Sep 30, 2025 | 958,000.00 |
| Sep 30, 2025 | 958,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -816,000.00 |
| Mar 31, 2025 | -816,000.00 |
| Dec 31, 2024 | -632,000.00 |
| Dec 31, 2024 | -632,000.00 |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | -25,000.00 |
| Mar 31, 2024 | -25,000.00 |
| Dec 31, 2023 | -274,000.00 |
| Dec 31, 2023 | -274,000.00 |